Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radium-223 safety checked in over 1,400 prostate cancer patients

NCT ID NCT02141438

Completed Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed over 1,400 men with metastatic castration-resistant prostate cancer who were already receiving Radium-223 as part of their routine care. Researchers tracked serious side effects and the development of new cancers over several years. The goal was to better understand the long-term safety of this treatment in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Radium-223 (Xofigo)

What this could lead to

If successful, this study could confirm the long-term safety of Radium-223 and help doctors better understand the risk of second cancers in men with advanced prostate cancer.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other treatments patients received.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

  • Study site

    Anchorage, Alaska, United States

  • Study site

    Scottsdale, Arizona, United States

  • Study site

    Daly City, California, United States

  • Study site

    Long Beach, California, United States

  • Study site

    Sacramento, California, United States

  • Study site

    San Diego, California, United States

  • Study site

    Colorado Springs, Colorado, United States

  • Study site

    Boca Raton, Florida, United States

  • Study site

    Fort Myers, Florida, United States

  • Study site

    Jacksonville, Florida, United States

  • Study site

    Lakewood Rch, Florida, United States

  • Study site

    Plantation, Florida, United States

  • Study site

    Atlanta, Georgia, United States

  • Study site

    Decatur, Georgia, United States

  • Study site

    Honolulu, Hawaii, United States

  • Study site

    Evanston, Illinois, United States

  • Study site

    Warrenville, Illinois, United States

  • Study site

    Wichita, Kansas, United States

  • Study site

    Ashland, Kentucky, United States

  • Study site

    New Orleans, Louisiana, United States

  • Study site

    Baltimore, Maryland, United States

  • Study site

    Rockville, Maryland, United States

  • Study site

    Towson, Maryland, United States

  • Study site

    Boston, Massachusetts, United States

  • Study site

    Troy, Michigan, United States

  • Study site

    St Louis, Missouri, United States

  • Study site

    Billings, Montana, United States

  • Study site

    Omaha, Nebraska, United States

  • Study site

    Lebanon, New Hampshire, United States

  • Study site

    Neptune City, New Jersey, United States

  • Study site

    Township, New Jersey, United States

  • Study site

    Buffalo, New York, United States

  • Study site

    East Setauket, New York, United States

  • Study site

    Lake Success, New York, United States

  • Study site

    Winston-Salem, North Carolina, United States

  • Study site

    Middleburg Heights, Ohio, United States

  • Study site

    Oklahoma City, Oklahoma, United States

  • Study site

    Springfield, Oregon, United States

  • Study site

    Abington, Pennsylvania, United States

  • Study site

    Charleston, South Carolina, United States

  • Study site

    Myrtle Beach, South Carolina, United States

  • Study site

    Nashville, Tennessee, United States

  • Study site

    Houston, Texas, United States

  • Study site

    Lubbock, Texas, United States

  • Study site

    San Antonio, Texas, United States

  • Study site

    Temple, Texas, United States

  • Study site

    Charlottesville, Virginia, United States

  • Study site

    Virginia Beach, Virginia, United States

  • Study site

    Seattle, Washington, United States

  • Study site

    Multiple Locations, Argentina

  • Study site

    Multiple Locations, Austria

  • Study site

    Multiple Locations, Belgium

  • Study site

    Multiple Locations, Canada

  • Study site

    Multiple Locations, Colombia

  • Study site

    Multiple Locations, Czechia

  • Study site

    Multiple Locations, Denmark

  • Study site

    Multiple Locations, France

  • Study site

    Multiple Locations, Germany

  • Study site

    Multiple Locations, Greece

  • Study site

    Multiple Locations, Israel

  • Study site

    Multiple Locations, Italy

  • Study site

    Multiple Locations, Luxembourg

  • Study site

    Multiple Locations, Mexico

  • Study site

    Multiple Locations, Netherlands

  • Study site

    Multiple Locations, Portugal

  • Study site

    Multiple Locations, Spain

  • Study site

    Multiple Locations, Sweden

  • Study site

    Multiple Locations, United Kingdom